Wealthcreatures.com
رفتن به کانال در Telegram
Visit us at www.wealthcreatures.com Driven by Fundamentals and Leveraging Technicals. All post are Only For Study & Educational Purpose.consult you Financial Advisor Before Investing or taking any position. DISCLAIMER:We r Not SEBI REGISTERED ANALYST.
نمایش بیشتر1 345
مشترکین
-124 ساعت
-47 روز
-1130 روز
در حال بارگیری داده...
کانالهای مشابه
ابر برچسبها
اشارات ورودی و خروجی
---
---
---
---
---
---
جذب مشترکین
سپتامبر '26
سپتامبر '26
+5
در 0 کانالها
اوت '26
+8
در 0 کانالها
Get PRO
ژوئیه '26
+6
در 0 کانالها
Get PRO
ژوئن '26
+6
در 0 کانالها
Get PRO
مه '26
+6
در 0 کانالها
Get PRO
آوریل '26
+7
در 0 کانالها
Get PRO
مارس '26
+5
در 0 کانالها
Get PRO
فوریه '26
+7
در 0 کانالها
Get PRO
ژانویه '26
+3
در 0 کانالها
Get PRO
دسامبر '25
+3
در 0 کانالها
Get PRO
نوامبر '25
+6
در 0 کانالها
Get PRO
اکتبر '25
+7
در 0 کانالها
Get PRO
سپتامبر '25
+11
در 0 کانالها
Get PRO
اوت '25
+8
در 0 کانالها
Get PRO
ژوئیه '25
+9
در 0 کانالها
Get PRO
ژوئن '25
+19
در 0 کانالها
Get PRO
مه '25
+13
در 0 کانالها
Get PRO
آوریل '25
+7
در 0 کانالها
Get PRO
مارس '25
+1
در 0 کانالها
Get PRO
فوریه '25
+7
در 0 کانالها
Get PRO
ژانویه '25
+27
در 0 کانالها
Get PRO
دسامبر '24
+40
در 0 کانالها
Get PRO
نوامبر '24
+49
در 0 کانالها
Get PRO
اکتبر '24
+48
در 0 کانالها
Get PRO
سپتامبر '24
+49
در 0 کانالها
Get PRO
اوت '24
+35
در 0 کانالها
Get PRO
ژوئیه '24
+33
در 0 کانالها
Get PRO
ژوئن '24
+26
در 0 کانالها
Get PRO
مه '24
+24
در 0 کانالها
Get PRO
آوریل '24
+33
در 0 کانالها
Get PRO
مارس '24
+15
در 0 کانالها
Get PRO
فوریه '24
+46
در 0 کانالها
Get PRO
ژانویه '24
+54
در 0 کانالها
Get PRO
دسامبر '23
+34
در 0 کانالها
Get PRO
نوامبر '23
+12
در 0 کانالها
Get PRO
اکتبر '23
+15
در 0 کانالها
Get PRO
سپتامبر '23
+17
در 0 کانالها
Get PRO
اوت '23
+16
در 0 کانالها
Get PRO
ژوئیه '23
+17
در 0 کانالها
Get PRO
ژوئن '23
+8
در 0 کانالها
Get PRO
مه '23
+8
در 0 کانالها
Get PRO
آوریل '23
+5
در 0 کانالها
Get PRO
مارس '23
+3
در 0 کانالها
Get PRO
فوریه '23
+6
در 0 کانالها
Get PRO
ژانویه '23
+7
در 0 کانالها
Get PRO
دسامبر '22
+9
در 0 کانالها
Get PRO
نوامبر '22
+14
در 0 کانالها
Get PRO
اکتبر '22
+19
در 0 کانالها
Get PRO
سپتامبر '22
+27
در 0 کانالها
Get PRO
اوت '22
+19
در 0 کانالها
Get PRO
ژوئیه '22
+7
در 0 کانالها
Get PRO
ژوئن '22
+14
در 0 کانالها
Get PRO
مه '22
+28
در 0 کانالها
Get PRO
آوریل '22
+43
در 0 کانالها
Get PRO
مارس '22
+48
در 0 کانالها
Get PRO
فوریه '22
+18
در 0 کانالها
Get PRO
ژانویه '22
+57
در 0 کانالها
Get PRO
دسامبر '21
+39
در 0 کانالها
Get PRO
نوامبر '21
+49
در 0 کانالها
Get PRO
اکتبر '21
+64
در 0 کانالها
Get PRO
سپتامبر '21
+56
در 0 کانالها
Get PRO
اوت '21
+65
در 0 کانالها
Get PRO
ژوئیه '21
+136
در 0 کانالها
Get PRO
ژوئن '21
+149
در 0 کانالها
Get PRO
مه '21
+128
در 0 کانالها
Get PRO
آوریل '21
+81
در 0 کانالها
Get PRO
مارس '21
+62
در 0 کانالها
Get PRO
فوریه '21
+49
در 0 کانالها
Get PRO
ژانویه '21
+44
در 0 کانالها
Get PRO
دسامبر '20
+485
در 0 کانالها
| تاریخ | رشد مشترکین | اشارات | کانالها | |
| 22 سپتامبر | 0 | |||
| 21 سپتامبر | 0 | |||
| 20 سپتامبر | 0 | |||
| 19 سپتامبر | 0 | |||
| 18 سپتامبر | 0 | |||
| 17 سپتامبر | 0 | |||
| 16 سپتامبر | 0 | |||
| 15 سپتامبر | 0 | |||
| 14 سپتامبر | 0 | |||
| 13 سپتامبر | 0 | |||
| 12 سپتامبر | +1 | |||
| 11 سپتامبر | 0 | |||
| 10 سپتامبر | 0 | |||
| 09 سپتامبر | +2 | |||
| 08 سپتامبر | 0 | |||
| 07 سپتامبر | +2 | |||
| 06 سپتامبر | 0 | |||
| 05 سپتامبر | 0 | |||
| 04 سپتامبر | 0 | |||
| 03 سپتامبر | 0 | |||
| 02 سپتامبر | 0 | |||
| 01 سپتامبر | 0 |
پستهای کانال
| 2 | AHCL
🔐 in 5% UC
28.86 🔥 | 318 |
| 3 | Anlon Healthcare
( AHCL )
20% 💥 🔥
27.48
Fresh ATH | 386 |
| 4 |  Laurus Labs
Latest presentation is an absolute stunner!
Top notch integrated pharma platform in making - Sky is the limit!
Study 📚 📖 | 442 |
| 5 | Azad Engg - 7%
CDSL - 3%
AHCL - 5%
Qpower - 3%
Adani port - 5% | 565 |
| 6 | Piramal pharma
Available @ 205
Opportunity | 625 |
| 7 | Nifty @ 23220
Nifty support @ 22800
& next Major strong 💪 support @ 22000-22300 zone
Let’s see where it gets stable
Next 30-60 days shld be Roller coaster ride | 669 |
| 8 | Stocks worth studying & Buying in Dips
If this correction gets deeper, these are the names I’ll be watching closely:
Azad Engineering
BSE Ltd
CDSL
Dolat Algo
Balaji Amines
Gland Pharma
Deepak Fertlizer
Wockhardt pharma
EKC
IOL Chemicals
QPower
Pitti Engineer
Bal Pharma
Raymond Ltd
Savita Oil Technologies
AHCL
IREDA
Waaree Energies
Adani port
Good stocks, better prices that’s where the opportunity lies.
Study 📚 each & every company
Looking Great for 12-18-24-30-36 months | 1 019 |
| 9 | Piramal pharma after hitting ATH 231.93
Now available @ 209
If anyone has patience for next 2-3 years
Study 📚 it
💪 support @ 198-204 zone | 949 |
| 10 | 𝐀𝐧𝐥𝐨𝐧 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐋𝐭𝐝
CMP - 18 - 18.50
Support @ 15 - 14.75
2030 vision
Yaad hai sakar healthcare in 2021 at just 200 -225 cr market cap
Everything takes Time
Just study & Compare price in 2030
High-growth small-cap pharma & API story.
Market cap is just 100cr high risk
But study if things go well this can be 500/1000cr ➕
fundamentally for long-term but I would treat it as a high-growth/high-risk small-cap rather than a “buy and forget” stock.
Disc - Only for educational and study 📚 purpose only. Consult your financial advisor before investing or taking any position based on above article | 937 |
| 11 | 𝐀𝐧𝐥𝐨𝐧 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐋𝐭𝐝
CMP - 18 - 18.50
Support @ 15 - 14.75
2030 vision
Yaar hai sakar healthcare in 2021 at just 200 -225 cr market cap
Everything takes Time
Just study & Compare price in 2030
High-growth small-cap pharma & API story.
Market cap is just 100cr high risk
But study if things go well this can be 500/1000cr ➕
fundamentally for long-term but I would treat it as a high-growth/high-risk small-cap rather than a “buy and forget” stock.
Disc - Only for educational and study 📚 purpose only. Consult your financial advisor before investing or taking any position based on above article | 11 |
| 12 | Wockhardt pharma
2000-2273 zone from last few session
Shld move out of this zone 🔜
Getting Ready for ATH 🔜
Stay Tunned | 756 |
| 13 | Netweb | 704 |
| 14 | Management commentary suggests strong growth over the next 2–3 years
🔹 Sakar Healthcare – ~25% revenue CAGR;
50%+ PAT growth
🔹 Netweb Technologies – 35–40% revenue growth guidance
🔹 Senores Pharma – 30–40% revenue & 50–60% PAT Growth
🔹Aarti Pharmalabs- 40–50% CDMO revenue growth &
Multi-fold profit scaling
Would keep adding more names where I feel confidence on management
& company
Study 📚 all above 👆 | 718 |
| 15 | ESDS
10% 🔥
FRESH ATH
1582
Start Booking profits | 736 |
| 16 | On Radar Cables & Conductor Theme
1.>RR Kabel
CMP - 2420
2.>Laser power
CMP - 290
3.> Lumino
CMP - 100-103
🔸The cable & conductor theme has a genuine structural tailwind from power transmission, distribution and infrastructure capex.
🔸But “cheap price” alone isn't enough—earnings growth, margins and valuation ultimately decide the return.
🔸RR Kabel,Laser Power & Lumino offer different exposures within the same broader theme.
🔸The interesting part is whether the sector's growth can sustain without competition eroding margins.
🔸With UltraTech entering wires and cables, competition is clearly becoming a factor.
🔸The next leg of the theme will belong to companies that can grow volumes without sacrificing returns.
Study 📚 all 3 companies | 734 |
| 17 | After
SAKAR HEALTHCARE
KWALITY PHARMA
WOCKHARDT PHARMA
PIRAMAL PHARMA
ONE API Turnaround stock worth studying 📖
Solara Active pharma
The turnaround Story Worth Watching 💊
When I look at pharma companies,
I like businesses that sit deep in the value chain.
Solara Active Pharma is one such company.
🔸Solara is a pure-play API manufacturer, with 60+ commercial APIs across therapeutic areas and customers across 70+ countries. It also operates in contract manufacturing.
🔸Think of it simply:
Before a pharma company can sell a medicine, it needs the active ingredient.
🔸That’s where Solara comes in Q1 FY27 🔥
Revenue: ₹381 Cr | +19.6% YoY
PAT: ₹16.3 Cr | +55% YoY
🔸The important part for me isn’t just revenue growth.
🔸Profitability is recovering much faster than the top line.
🔸And that comes after a difficult period for the company, making the turnaround story particularly interesting.
Why I like Solara
• Pure-play API business
• 60+ commercial APIs
• Presence across 73+ countries
• Exposure to anti-infectives, anti-parasitics and other key therapeutic segments
• Opportunity to benefit from global pharma supply-chain diversification
• Improving profitability can create significant operating leverage
🔸The pharma industry is increasingly looking for reliable, diversified API suppliers outside China.
🔸If Solara can continue its margin recovery while growing its API and contract-manufacturing business, the earnings trajectory could look very different from what the market has seen over the last few years.
🔸Solara is not just another pharma stock.
🔸It’s a pure-play API turnaround story and Q1 FY27 suggests the recovery is gaining momentum.
CMP - 690-700
Support - 580-550
Shld do well in 12-24-36 months
Study 📚 📖 it to get more confidence
Disc - All views expressed are personal and only for educational and study purpose. Consult your financial advisor before investing or taking any position based on above article. | 600 |
| 18 |  +1Signet Ltd
Promoter buying is getting interesting.
One small-cap is seeing repeated accumulation from its promoter.
Mukesh Sangla, Promoter & Director, has been buying shares across multiple periods.
Dec 2025: 38,364
Feb 2026: 55,995+
Mar 2026: 57,285
Aug 2026: 1,47,869
Sep 2026: 39,391
That’s roughly 3.4 lakh shares accumulated in the transactions visible here.
The bigger signal?
The buying has been spread across months.
For small-caps, I pay close attention when promoter buying combines with improving business numbers, capacity expansion and a stronger earnings outlook.
Promoter buying alone is never a thesis.
But when insider conviction + business growth + capex start aligning, the setup becomes worth researching deeper.
Study 📖 📚
Not a recommendation. Do your own research. | 657 |
| 19 | Gayatri Projects — Strong Q1 FY27 Turnaround
CMP - 22-23.50
Support @ 18
Revenue from operations: ₹228.77 Cr vs ₹76.58 Cr YoY — nearly 3x
Consolidated Net Profit: ₹37.12 Cr vs ₹0.58 Cr loss YoY
📊 Profit before exceptional items & tax: ₹58.61 Cr vs ₹0.72 Cr loss YoY
🔹 Company also completed a ₹277.10 Cr preferential allotment during the quarter.
🔹 PNB has approved a ₹135.06 Cr One-Time Settlement (OTS); management is negotiating sale of mortgaged property to fund the settlement.
A significant operational turnaround, but the debt-settlement execution remains an important factor to watch.
Study 📖 it | 654 |
| 20 |  Good ipo for listing Gains and also for Longterm | 603 |
